Cellular therapies have shown increasing promise as a cancer treatment. Encouraging results against hematologic malignancies are paving the way to move into solid tumors. In this review, we will focus on T-cell therapies starting from tumor infiltrating lymphocytes (TILs) to optimized T-cell receptor-modified (TCR) cells and chimeric antigen receptor-modified T cells (CAR-Ts). We will discuss the positive preclinical and clinical findings of these approaches, along with some of the persisting barriers that need to be overcome to improve outcomes.

中文翻译：

---

过继性 T 细胞疗法：增强免疫系统以对抗癌症

细胞疗法已显示出越来越多的癌症治疗前景。针对血液系统恶性肿瘤的令人鼓舞的结果正在为进入实体瘤铺平道路。在这篇综述中，我们将重点关注 T 细胞疗法，从肿瘤浸润淋巴细胞 (TIL) 到优化的 T 细胞受体修饰 (TCR) 细胞和嵌合抗原受体修饰的 T 细胞 (CAR-T)。我们将讨论这些方法的积极的临床前和临床发现，以及一些需要克服以改善结果的持续障碍。